Looking to the future: focus on DPP-4 inhibitors for the treatment of type 2 diabetes and emerging therapies (Q40108641)

17 September 2017

Looking to the future: focus on DPP-4 inhibitors for the treatment of type 2 diabetes and emerging therapies (English)

1 reference

17 September 2017

1 reference

Joshua J Neumiller

1

1 reference

17 September 2017

Peggy Soule Odegard

2

1 reference

17 September 2017

John R White

3

1 reference

17 September 2017

Stephen M Setter

4

1 reference

17 September 2017

R Keith Campbell

5

1 reference

17 September 2017

language of work or name

1 reference

1 March 2008

1 reference

The Science of Diabetes Self-Management and Care

17 September 2017

1 reference

17 September 2017

34

1 reference

17 September 2017

2

1 reference

17 September 2017

183-200

1 reference

Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report

17 September 2017

1 reference

https://api.crossref.org/works/10.1177%2F0145721708316620

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0145721708316620

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0145721708316620

Evaluation of alternative strategies for optimizing glycemia: progress to date

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0145721708316620

Dipeptidyl peptidase IV inhibitors: a promising new therapeutic approach for the management of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0145721708316620

Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0145721708316620

Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0145721708316620

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0145721708316620

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0145721708316620

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0145721708316620

Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0145721708316620

Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0145721708316620

Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0145721708316620

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0145721708316620

Dose-response relationship of oral insulin spray in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0145721708316620

Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0145721708316620

21 January 2018

Identifiers

DOI

10.1177/0145721708316620

1 reference

17 September 2017

1 reference